Was it a plane? Was it a UFO? Bright light over Quebec captivates stargazers
In a publication on Facebook, the Astrolab du parc national du Mont-Mégantic in Quebec's Eastern Townships described it as "a magnificent and luminous spiral streaking across the sky at around 10:40 p.m."
Several people in the Montreal area also witnessed the strange phenomenon and reached out to CBC News describing a bright light enveloped by a fuzzy halo and warning of a UFO sighting.
While it was certainly unusual, it wasn't really an unidentified flying object, but more likely the result of a rocket launch, according to the Astrolab.
"It was in all likelihood the second stage of an Ariane 6 rocket which was igniting its engine in order to de-orbit itself after having released the European satellite Metop-SGA1 in a polar orbit," the Facebook post explained.
The European Space Agency confirmed on its website that a weather satellite was launched Tuesday evening at 9:37 p.m. local time, from the European spaceport in Kourou, French Guiana — an overseas department of France located in South America.
The new satellite is meant to usher in "a new era of weather and climate monitoring from polar orbit."
WATCH | What was that bright object flying in the sky over Quebec:
According to astrophysicist Robert Lamontagne, the rocket's orbit is what allowed for the spectacle to be visible in Quebec.
Most of the time rocket launches are on an equatorial orbit and so will be visible near the equator, he said.
In a polar orbit, the rocket has to go around the earth circling each pole of the planet.
"So the the trajectory of that the rocket made it so that from our latitude it could be seen in Montreal or the south of Quebec," he said.
But to witness the phenomena, other factors also need to align, according to Lamontagne, including the time of launch and the altitude reached by the rocket.
"From our point of view, we were in the dark, the sun was low below the horizon, but the rocket itself was so high that it was still lit by the by the sun," he said.
And as the second stage of the rocket re-entered the earth's atmosphere, he said, "it was spinning a little bit, there was exhaust gases coming out from it and that's what people saw in the sky."
A spokesperson for the Canadian Space Agency told CBC News that many observers captured video of the event, with the agency confirming it was the ESA's Ariane 6 rocket.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
16 hours ago
- Medscape
Tibremciclib for Advanced Breast Cancer: Is It Worth It?
Adding the novel CDK4/6 inhibitor tibremciclib (Betta Pharmaceuticals) to second-line fulvestrant significantly extended progression-free survival (PFS) in patients with HR-positive/HER2-negative advanced breast cancer, but with the tradeoff of increased toxicity, new data suggest. Compared with fulvestrant alone, the combination prolonged median PFS for these patients by 11 months, according to results from the phase 3 TIFFANY trial. However, similar to existing CDK4/6 inhibitors, the tibremciclib-fulvestrant combination added to treatment side effects — including substantially higher rates of diarrhea, hematologic toxicities, and hypokalemia. The authors of the analysis, published in JAMA Oncology , described the toxicities as "manageable," emphasizing that few patients stopped treatment because of them. Study author Xichun Hu, MD, of Fudan University Shanghai Cancer Center, told Medscape Medical News that tibremciclib compares favorably with other CDK4/6 inhibitors in terms of dose reduction and discontinuation rates. However, Hu noted, that's based on cross-trial comparisons, which have to be interpreted with caution. Kathy Miller, MD, who was not involved in the trial, had a similar take. 'Toxicity actually looks similar to ribociclib and palbociclib, with primarily myelosuppression and little non-heme toxicity,' Miller, of the Melvin and Bren Simon Comprehensive Cancer Center at Indiana University, told Medscape Medical News. Tibremciclib plus fulvestrant was recently approved in China for HR-positive/HER2-negative advanced breast cancer following results from the trial, but the combination has yet to be approved in the US. The Benefits vs the Risks In the trial, Hu and colleagues studied the safety and efficacy of the new agent among patients from 69 centers in China who had experienced progression while on endocrine therapy and had received no more than one line of chemotherapy. A total of 274 patients were randomized (2:1) to receive either tibremciclib (400 mg orally, once daily) or placebo plus fulvestrant until disease progression, death, or treatment discontinuation over a median follow-up of 13 months. Eighty patients (43.5%) in the tibremciclib arm and 64 (71.1%) in the placebo arm experienced a PFS event (disease progression or death). Tibremciclib plus fulvestrant significantly improved PFS to 16.5 months versus 5.6 months with fulvestrant alone, reducing the risk of progression by 63% (hazard ratio [HR], 0.37; P < .001). As for safety, adverse events were higher in the treatment arm. The most common treatment-emergent adverse events were diarrhea (79.3% in the tibremciclib arm vs 13.3% in placebo arm), neutropenia (75.5% vs 15.6%), leukopenia (73.9% vs 16.7%), and anemia (69% vs 21.1%). Nausea and vomiting were also more common with tibremciclib, at 37% and 40.2%, respectively — versus 18.9% and 11.1% in the placebo group. Most often, those adverse events were grade 1 or 2. However, 50.5% of patients in the tibremciclib group had a grade 3 or higher treatment-emergent adverse event, versus 21.1% in the placebo group. The most common were neutropenia (15.2% vs 5.6%), anemia (12.0% vs 4.4%), and hypokalemia (12% vs 0%). Hypokalemia was often due to diarrhea and was managed with electrolyte monitoring and potassium supplementation, Hu said. One-third of patients in the tibremciclib arm developed hypertriglyceridemia (5.4% grade 3 or higher) — a rate higher than that seen with other CDK4/6 inhibitors. Cases were managed with lipid-lowering agents such as atorvastatin. More patients on tibremciclib experienced dosing interruptions due to adverse events (54% vs 23%), and dose reductions were also more common with the combination therapy (18.5% vs 4.4%). However, only four patients (all in the tibremciclib arm) discontinued treatment due to side effects. Overall, the adverse event profile of tibremciclib lines up with that of other CDK4/6 inhibitors and comes with better PFS, Hu said, noting that "the benefit-risk balance of tibremciclib plus fulvestrant appears highly favorable." In TIFFANY, the authors note d that cases of neutropenia and leukopenia were numerically lower than in trials of abemaciclib, dalpiciclib, and palbociclib plus fulvestrant. According to Hu, tibremciclib is structurally different from other drugs in its class, with a greater selectivity for CDK4 and less inhibition of CDK6 and CDK9, which may reduce the incidence of neutropenia as well as severe diarrhea. Plus, the PFS improvement seen in TIFFANY was greater, Hu said. Pa lbociclib in PALOMA-3 showed a median PFS of 9.5 months vs 4.6 months for fulvestrant alone (HR, 0.46); abemaciclib in MONARCH led to a PFS of 11.5 months vs 5.6 months (HR, 0.38, a Chinese population); and dalpiciclib in DAWNA-1 achieved 16.6 months vs 7.2 months (HR, 0.50, also in Chinese patients). While these are cross-trial comparisons, it's still unclear exactly how tibremciclib stacks up against other drugs in its class (including its impact on overall survival). The authors also caution that, because the trial exclusively enrolled Chinese patients without prior CDK4/6 inhibitor exposure, the findings may not be generalizable to broader populations, particularly in regions like North America and Europe. Miller pointed to the generalizability question as well, noting that fulvestrant monotherapy is typically not the standard of care in the US and other Western countries. 'This [study] joins a long list of second-line endocrine studies that show drug activity but don't compare to standard of care and don't really tell us how to best use the drug,' Miller said.
Yahoo
17 hours ago
- Yahoo
SpaceX Falcon 9 rocket to launch more Starlink satellites from Florida Thursday morning
The Brief SpaceX will launch 28 Starlink satellites Thursday around 8:30 a.m. from Cape Canaveral. The mission supports the expansion of the Starlink internet network. The Falcon 9 booster will fly for the 10th time and land on a droneship in the Atlantic. CAPE CANAVERAL, Fla. - SpaceX is gearing up for another Starlink satellite launch from Florida on Thursday morning. What we know A Falcon 9 rocket is set to launch 28 satellites into low-Earth orbit from Space Launch Complex 40 (SLC-40) at Cape Canaveral Space Force Station. The launch is part of SpaceX's ongoing mission to build a global broadband network through its rapidly growing Starlink constellation. Liftoff is set for around 8:30 a.m. FOX 35 will stream it live using the video player at the top of this page. By the numbers This will be the 10th flight for the first stage booster supporting this mission, which previously launched Crew-9, RRT-1, Firefly Blue Ghost Mission 1, Fram2, SXM-10, MTG-S1, and three Starlink missions. Following stage separation, the first stage will land on the Just Read the Instructions droneship, which will be stationed in the Atlantic Ocean. The Source This story was written based on information shared by SpaceX on August 14, 2025.
Medscape
20 hours ago
- Medscape
Simple, Noninvasive Eye Tracking May Flag Cognitive Decline
Naturalistic gaze patterns appear to be a simple, noninvasive, and reliable indicator of cognitive decline, new research suggested. Investigators found that gaze patterns during image viewing mirrored memory performance and distinguished healthy adults from those at risk for, or with, cognitive impairment. 'We are still in the early stages of establishing eye tracking as a marker of memory and cognitive status,' lead investigator Jordana S. Wynn, PhD, assistant professor of psychology at the University of Victoria, British Columbia, Canada, told Medscape Medical News . Although larger, more diverse, and longitudinal research validation is warranted, 'this work lays important groundwork by demonstrating that naturalistic eye movement patterns are meaningfully related to memory function,' she added. The study was published online on August 11 in the Proceedings of the National Academy of Sciences. Novel Research Because the fovea — a small, cone-dense region at the center of the retina — captures high-resolution detail only in the center of the visual field, the eyes must constantly move to sample the full environment. These movements provide a precise, noninvasive measure of how visual information is encoded and retrieved from memory. While prior research has linked certain gaze metrics to memory decline, it remains unclear how multivariate gaze patterns — considering multiple eye movement features together — relate to memory function. For the study, which researchers note is the first work to analyze how eye movements differ across a range of brain health and memory function levels, Wynn and colleagues assessed 106 individuals across five groups — young adults, healthy older adults, individuals at risk for significant cognitive decline, those with mild cognitive impairment (MCI), and those with amnesia. They hypothesized that changes in gaze patterns would correspond in a linear fashion to cognitive function from the healthiest participants to those with amnesia. The study included two experiments. In the first, participants viewed a series of 120 distinct images, each for 5 seconds, to assess 'idiosyncratic gaze similarity,' or the uniqueness of their viewing patterns. As expected, memory function declined across groups — from young adults to healthy older adults, then to the at-risk group, followed by individuals with MCI and those with amnesia, showing a 'meaningful linear relationship.' In the second experiment, investigators used the same set of images, presenting 60 images once and another 60 three times for 5 seconds each to measure 'repetitive gaze similarity.' This approach revealed whether participants consistently encoded the same image features each time on repeat viewings or if they updated their memory with different features, indicating stronger or more flexible memory encoding. The researchers found that the healthy young adult group encoded unique image features with each image presentation. In contrast, participants with decreased memory and/or hippocampal/medial temporal function tended to focus on the same features each time they saw the same image. These results confirm that memory decline is associated with reduced visual exploration, less effective updating of encoded representations over repeated exposures, and lower differentiation of the images. Exciting, but Not Surprising Wynn said she was not particularly surprised by the study findings. 'Our previous work in healthy populations provided evidence that the brain and cognitive systems supporting eye movements and memory are closely linked. In past experimental work, we found that certain gaze patterns were predictive of memory performance,' she said. Therefore, Wynn and colleagues postulated that memory decline from aging, disease, or injury would yield similar changes in eye movements. 'That our prediction was confirmed was certainly exciting, but not surprising,' she added. The investigators concluded that the results provide 'compelling evidence that naturalistic gaze patterns can serve as a sensitive marker of cognitive decline.' This research lays a foundation for future work using multivariate gaze metrics to diagnose and track memory and/or hippocampal/medial temporal lobe function, they added. It's too early to determine whether naturalistic eye movements could become a first-line screening tool for cognitive decline, Wynn said. 'The value of eye tracking compared to standard neuropsychological tests is that it is noninvasive, cost-effective, and perhaps most importantly, universal,' she noted. Nearly anyone — regardless of age, ability, or language — can view pictures on a screen, so creating a screening tool that doesn't rely on written or verbal responses would be particularly practical, Wynn said. It is still too early to know whether naturalistic eye movements could serve as a first-line screening tool for cognitive decline. Wynn noted that eye tracking is noninvasive, cost-effective, and broadly accessible — anyone, regardless of age, ability, or language, can view images on a screen. With further refinement, she said, these measures could provide a high-resolution way to monitor memory and brain function in clinical settings. Novel Insights Commenting on the research for Medscape Medical News , Mariam Aly, PhD, acting associate professor of psychology at the University of California, Berkeley, said the study 'yields novel insights into how the way people move their eyes can contribute to, and reflect, memory impairments.' 'This elegant study uses sophisticated analyses to provide a comprehensive picture of how eye movement patterns differ across groups that span a continuum of memory abilities.' Importantly, these differences in eye movements were apparent even though participants had no explicit task, added Aly, who was not affiliated with the research. 'This means that assessment of eye movements during natural viewing of images has the potential to be developed into an important tool for detecting memory decline in clinical settings,' she said.
